Skip to content

Change in AP at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$409M+581%
Johnson & Johnson logo
Johnson & JohnsonJNJ
-$3.92B-84.4%
Merck & Co. logo
Merck & Co.MRK
$27.5M-39.6%
Gilead Sciences logo
Gilead SciencesGILD
-$67M+36.2%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
Kymera Therapeutics logo
Kymera TherapeuticsKYMR

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableTrade.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s change in AP?
ImmunityBio, Inc. (IBRX) reported change in AP of $3.9M in Q1 2026.
How has ImmunityBio, Inc.'s change in AP changed year-over-year?
ImmunityBio, Inc.'s change in AP decreased by 39.4% year-over-year, from $6.44M to $3.9M.
What is the long-term trend for ImmunityBio, Inc.'s change in AP?
Over 3 years (2021 to 2024), ImmunityBio, Inc.'s change in AP has grown at a -5.2% compound annual growth rate (CAGR), from -$3.72M to -$3.17M.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.